Xastellas BEYOND Unveiling the hidden truth of anaemia

91%

Awareness of anaemia of chronic kidney disease (CKD) at diagnosis



Getting a diagnosis of anaemia of CKD



of nephrologists stated

that they immediately

started treatment for

a diagnosis

their patients following

Patients reported feeling that the diagnosis process was frustrating, yet nephrologists underestimated the logistical impact this could have for patients

However, patients reported different timeframes:

55% immediately on treatment

29% on treatment in 3 months

16% after 3 months

89% of nephrologists reported providing information around treatment options for their patients

45%

of patients reported they were provided with information about treatment options

Leaving 37%

of patients wanting to know more about their condition

Astellas Pharma, CKD anaemia patient and nephrologist market research, Data on File NEPH_2020_0145 NEPH_2020_0182_APE | Date of preparation: July 2020 © 2020 Astellas Pharma Europe Ltd. Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.

Undiagnosed anaemia of CKD

Nearly one-third (31%) of the nephrologists surveyed believed that over 91% of their CKD patients had undiagnosed anaemia

> Only 1 in 3 CKD patients (36%) surveyed felt well informed of the long-term implications of not being treated for

their anaemia

76% of nephrologists surveyed felt well informed and that untreated anaemia could lead to a long-term impact on a patient's health, such as

> Increased cardiovascular risk (79%)

Diminished health-related quality of life (78%)

Increased combined morbidity and mortality (70%)

Management of anaemia of CKD





This research was conducted on behalf of Astellas by The Research Partnership, between January and February 2020. A total of 200 nephrologists and 203 patients with anaemia of CKD were surveyed in five European markets: France, Germany, Spain, UK, Italy. Due to national regulations, Astellas did not undertake research with patients in Italy. Participants completed 25minute online interviews.

The burden of living with anaemia of CKD



Surveyed nephrologists appeared to be **more aware of the physical burden (78%)** of the disease **than the emotional burden (23%)**



66% of patients reported having a caregiver to help with: p

On average, patients reported missing more than **8 days of work** per month due to their symptoms

Tasks around the house (67%) Taking medication (51%) Travelling to appointments (45%) Liaising with healthcare professionals (23%)

Hope for the future management of anaemia of CKD

Surveyed patients' top three hopes:



Surveyed nephrologists' top three hopes:



Astellas Pharma, CKD anaemia patient and nephrologist market research, Data on File NEPH_2020_0145 NEPH_2020_0182_APE | Date of preparation: July 2020

O182_APE | Date of preparation: July 2020_ © 2020 Astellas Pharma Europe Ltd.

Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.